OncoMatch/Clinical Trials/NCT05483400
Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors
Is NCT05483400 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Tiragolumab and atezolizumab for head and neck neoplasms.
Treatment: Tiragolumab and atezolizumab — In this open label phase II trial combination therapy with the anti-PD-L1 antibody atezolizumab and the anti-TIGIT antibody tiragolumab will be investigated in patients with localized HNSCC who will undergo surgery, advanced or metastatic MSI-H cancer, PD-1 resistant metastatic melanoma, and patients with a locally advanced or metastatic solid tumor who, in the opinion of the investigator, based on available clinical data, may benefit from treatment with anti-PD-L1 and anti-TIGIT immunotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Head and Neck Squamous Cell Carcinoma
Melanoma
Biomarker criteria
Required: PD-L1 (CD274) expression (CD8 imaging substudy participation required if slots available)
Participate in the GE-269-001 CD8 investigational imaging trial provided that there are slots is that trial.
Disease stage
Required: Stage CLINICAL T2-4A, NODE POSITIVE
clinical T2-4a, or node positive resectable HPV-unrelated HNSCC
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: immune checkpoint inhibitor (anti-PD1, anti-PD-L1)
Exception: only for cohort 1, 2 and 4
Prior immune checkpoint inhibitor treatment, including but not limited to anti-PD1 and anti-PD-L1 antibodies (only for cohort 1, 2 and 4)
Lab requirements
Blood counts
hemoglobin ≥9.0 g/dL; platelet count ≥100 x 10^9
Kidney function
serum creatinine ≤1.5 x ULN or estimated GFR > 30 mL/min/1.73 m2; 24-hour urine creatinine collection may substitute
Liver function
total bilirubin ≤1.5 x ULN (≤3 x ULN if liver tumor involvement); AST ≤2.5 x ULN (≤5 x ULN if liver tumor involvement); ALT ≤2.5 x ULN (≤5 x ULN if liver tumor involvement); ALP ≤2.5 x ULN (≤5 x ULN if liver or bone tumor involvement); Gilbert's syndrome exception
Adequate organ and bone marrow function defined as: hemoglobin ≥9.0 g/dL; platelet count ≥100 x 10^9; serum creatinine ≤1.5 x ULN or estimated GFR > 30 mL/min/1.73 m2. Adequate hepatic function defined as: total bilirubin ≤1.5 x ULN (≤3 x ULN if liver tumor involvement); AST ≤2.5 x ULN (≤5 x ULN if liver tumor involvement); ALT ≤2.5 x ULN (≤5 x ULN if liver tumor involvement); ALP ≤2.5 x ULN (≤5 x ULN if liver or bone tumor involvement). Gilbert's syndrome exception.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05483400 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior immune checkpoint inhibitor disqualifies patients from enrollment.
Does this trial require CD274?
Yes, CD274 expression (CD8 imaging substudy participation required if slots available) is a required biomarker for enrollment.
What disease stage is eligible?
Stage CLINICAL T2-4A or NODE POSITIVE is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify